3.1. Mitazalimab Induces Transient Peripheral Transcriptomic Alterations in Patients with Advanced Solid Tumors
malignancies
MALIGNANCIES
We analyzed RNA sequencing data from a subgroup of patients from four selected dose levels, with a total of 38 patients, from a clinical Phase I study investigating intravenous mitazalimab administration at escalating doses. The patients had a median age of 56 years (range 18–77 years) and had undergone a median of three previous systemic treatments (range 0–9) for their malignancies and had exhausted their standard treatment options prior to participating in the study with mitazalimab (To assess the effects of mitazalimab, we first analyzed patients who did not receive pretreatment with corticosteroids (